CTRI/2022/01/039090已完成4 期
To compare the effect of vildagliptin with metformin versus glimepiride with metformin on inflammatory markers and glycaemic control in type2 diabetes mellitus patients - VilMeGliMeD
avreet Kaur0 个研究点目标入组 80 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients above 18 years old age, of either sex with type 2 diabetes mellitus
- •Newly diagnosed type 2 diabetes mellitus patient with HBA1C >8%
排除标准
- •Other types of diabetes
- •patients with inflammatory disease (inflammatory bowel disease, lupus, arthritis), hepatic or renal impairment, malignancy, thrombosis and conditions other than type 2 diabetes mellitus
- •Who are on steroids, anti-inflammatory and immunomodulatory drugs
研究者
相似试验
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
已完成
4 期
Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CADDiabetes Mellitus, Type 2Coronary Artery DiseaseNCT03693560Damanhour University80
未知
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220294ovartis Pharma K.K.370
已完成
4 期
Comparison of utility of Viladagliptin 50 mg tablet twice daily and metformin combination therapy with Vildagliptin 100 mg sustained release tablet once daily and metformin combination therapy in Indian patients with type 2 diabetes mellitus: A randomized open label phase IV clinical trialCTRI/2021/10/037574Dr Rudra Paul
未知
3 期
To Compare the Effect with Vildagliptin (50mg qd, 50mg bid or 100mg qd) to Placebo in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220283ovartis Pharma K.K.236